David A. Braun, MD, PhD

Cieri N, Hookeri N, Stromhaug K, Stevens J, Kooshesh K, Klaeger S, Clauser K, Sarkizova S, Braun D, Penter L, Oliveira G, Kim H, Lane W, Li S, Livak K, Ho V, Ritz J, Soiffer R, Keskin D, Stewart C, Gusev A, Getz G, Wu C. Systematic Identification of Autosomal and Y-Encoded Minor Histocompatibility Antigens Reveals Predictors of Chronic Gvhd and Candidate GVL Targets Blood 2022, 140: 4762-4764. DOI: 10.1182/blood-2022-162841.

Iorgulescu B, Liu S, Li S, Borji M, Barrera-Lopez I, Shanmugam V, Lyu H, Morriss J, Garcia Z, Murray E, Reardon D, Yoon C, Braun D, Livak K, Wu C, Chen F. 115 Spatial dissection of T cell clonotype identity, transcriptional profiles, and cell-cell interactions in the tumor microenvironment and tertiary lymphoid structures 2022, a127-a127. DOI: 10.1136/jitc-2022-sitc2022.0115.

Liu S, Iorgulescu J, Li S, Borji M, Barrera-Lopez I, Shanmugam V, Lyu H, Morriss J, Garcia Z, Murray E, Reardon D, Yoon C, Braun D, Livak K, Wu C, Chen F. Spatial maps of T cell receptors and transcriptomes reveal distinct immune niches and interactions in the adaptive immune response Immunity 2022, 55: 1940-1952.e5. PMID: 36223726, PMCID: PMC9745674, DOI: 10.1016/j.immuni.2022.09.002.

Labaki C, Bakouny Z, Sanglier T, Schmidt A, Shim J, Braun D, Bouquet F, Joyce M, Xie W, Tolaney S, Choueiri T. 252P Real-world progression-free survival (rwPFS) and time to next line of therapy (TTNT) as intermediate endpoints for survival in metastatic breast cancer: A real-world experience Annals Of Oncology 2022, 33: s652. DOI: 10.1016/j.annonc.2022.07.291.

Denize T, Hou Y, Pignon J, Walton E, West D, Freeman G, Braun D, Wu C, Gupta S, Motzer R, Atkins M, McDermott D, Choueiri T, Shukla S, Signoretti S. Transcriptomic Correlates of Tumor Cell PD-L1 Expression and Response to Nivolumab Monotherapy in Metastatic Clear Cell Renal Cell Carcinoma. Clinical Cancer Research 2022, 28: 4045-4055. PMID: 35802667, PMCID: PMC9481706, DOI: 10.1158/1078-0432.ccr-22-0923.

Adib E, Nassar A, El Zarif T, Kale N, Rakaee M, Mouhieddine T, Abou Alaiwi S, Freeman D, Labban M, Akl E, Haddad R, Hodi F, Sonpavde G, Giannakis M, Braun D, Gusev A, Choueiri T, Overstreet E, Stone E, Kwiatkowski D. Dual CDKN2A/MTAP loss compared to CDKN2A loss alone and response to immune-checkpoint inhibitors (ICI) in advanced solid tumors. Journal Of Clinical Oncology 2022, 40: 2622-2622. DOI: 10.1200/jco.2022.40.16_suppl.2622.

Saliby R, Jammihal T, Labaki C, Xie W, Motzer R, Powles T, Rini B, Albiges L, Pal S, McKay R, Signoretti S, Shukla S, Van Allen E, Braun D, Choueiri T. Cross-trial validation of molecular subtypes in patients with metastatic clear cell renal cell carcinoma (RCC): The JAVELIN Renal 101 experience. Journal Of Clinical Oncology 2022, 40: 4531-4531. DOI: 10.1200/jco.2022.40.16_suppl.4531.

Labaki C, Zhang L, Hou Y, Bi K, Hobeika C, Bakouny Z, Camp S, Priolo C, Khabibullin D, Schindler N, Alchoueiry M, Denize T, Saliby R, Matar S, Signoretti S, Van Allen E, Shukla S, Braun D, Henske E, Choueiri T. Molecular characterization of the tumor microenvironment in chromophobe renal cell carcinoma (ChRCC) and related oncocytic neoplasms. Journal Of Clinical Oncology 2022, 40: 4549-4549. DOI: 10.1200/jco.2022.40.16_suppl.4549.

Labaki C, Bakouny Z, Sanglier T, Schmidt A, Shim J, Braun D, Bouquet F, Joyce M, Xie W, Tolaney S, Choueiri T. Real-world progression-free survival (rwPFS) and time to next line of therapy (TTNT) as intermediate endpoints for survival in metastatic breast cancer: A real-world experience. Journal Of Clinical Oncology 2022, 40: 6520-6520. DOI: 10.1200/jco.2022.40.16_suppl.6520.

Xu W, Bharadwaj M, Birch G, Schindler N, Labaki C, Saliby R, Bakouny Z, Freeman D, O'Toole J, Lee G, McGregor B, Hirsch M, Shukla S, McDermott D, Signoretti S, Romee R, Choueiri T, Braun D. Single cell transcriptomic characterization of natural killer (NK) cell populations in clear cell renal cell carcinoma and association with clinical outcomes. Journal Of Clinical Oncology 2022, 40: e16521-e16521. DOI: 10.1200/jco.2022.40.16_suppl.e16521.

Saliby R, Labaki C, Xie W, Nonato T, Schmidt A, Bakouny Z, Xu W, Ravi P, Braun D, Hirsch M, McKay R, Choueiri T, McGregor B. Fumarate hydratase-deficient renal cell carcinoma: The real-world experience at Dana-Farber Cancer Institute and Moores Cancer Center. Journal Of Clinical Oncology 2022, 40: e16522-e16522. DOI: 10.1200/jco.2022.40.16_suppl.e16522.

Braun DA, Wu CJ. Tumor-Infiltrating T Cells — A Portrait New England Journal Of Medicine 2022, 386: 992-994. PMID: 35263526, DOI: 10.1056/nejmcibr2119477.

Atkins M, Jegede O, Haas N, McDermott D, Bilen M, Stein M, Sosman J, Alter R, Plimack E, Ornstein M, Hurwitz M, Peace D, Signoretti S, Denize T, Cimadamore A, Braun D, Wu C, Einstein D, Catalano P, Hammers H. Phase II study of nivolumab and salvage nivolumab + ipilimumab in treatment-naïve patients (pts) with advanced clear cell renal cell (HCRN GU16-260-Cohort A): Final report. Journal Of Clinical Oncology 2022, 40: 288-288. DOI: 10.1200/jco.2022.40.6_suppl.288.

Liu S, Iorgulescu B, Li S, Morriss J, Borji M, Murray E, Braun D, Livak K, Wu C, Chen F. 76 Spatial mapping of T cell receptors and transcriptomes in renal cell carcinoma following immune checkpoint inhibitor therapy Journal For ImmunoTherapy Of Cancer 2021, 9: a84-a85. DOI: 10.1136/jitc-2021-sitc2021.076.

Oliveira G, Stromhaug K, Klaeger S, Cieri N, Iorgulescu B, Li S, Braun D, Neuberg D, Carr S, Livak K, Tompers D, Fritsch E, Wind-Rotolo M, Hacohen N, Sade-Feldman M, Keskin D, Ott P, Rodig S, Boland G, Wu C. 655 Landscape of helper and regulatory CD4+ T cells in melanoma Journal For ImmunoTherapy Of Cancer 2021, 9: a684-a684. DOI: 10.1136/jitc-2021-sitc2021.655.

Tsai F, Guercio B, Stuver S, Stern R, Peluso M, Winkler M, Piawah S, Vallurupalli M, Luskin M, Braun D, Parent A, Glotzbecker B, Kilbridge K. Resident-Reported Impact of a Novel Oncology Curriculum for Internal Medicine Residents Journal Of Cancer Education 2021, 37: 1879-1885. PMID: 34480712, PMCID: PMC8417651, DOI: 10.1007/s13187-021-02055-6.

Wang Y, Buck A, Grimaud M, Kodangattil S, Razimbaud C, Fayed A, Chang M, Culhane A, Braun D, Choueiri T, Wu C, Wei K, Chan L, Piel B, Ivanova E, Paweletz C, Barbie D, Jennings R, Ficial M, Sticco-Ivins M, Signoretti S, Freeman G, Zhu Q, Marasco W. Abstract 62: Development of dual-targeted fine-tuned immune restoring (DFIR) CAR T cell therapy for clear cell renal cell carcinoma (ccRCC) Cancer Research 2021, 81: 62-62. DOI: 10.1158/1538-7445.am2021-62.

Labaki C, Alaiwi S, Schmidt A, Zarif T, Bakouny Z, Nuzzo P, Xu W, Braun D, McGregor B, Choueiri T. Effect of high-dose corticosteroid use on efficacy of immune checkpoint inhibitors in patients with renal cell carcinoma (RCC). Journal Of Clinical Oncology 2021, 39: 4583-4583. DOI: 10.1200/jco.2021.39.15_suppl.4583.

McGregor B, Xie W, Bilen M, Braun D, Xu W, Ravi P, Heath E, McDermott D, McKay R, Hammers H, Choueiri T. Cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) (CaNI) for advanced renal cell carcinoma with variant histology (aRCCVH). Journal Of Clinical Oncology 2021, 39: tps4592-tps4592. DOI: 10.1200/jco.2021.39.15_suppl.tps4592.

Wang Y, Buck A, Grimaud M, Kodangattil S, Razimbaud C, Fayed A, Chang M, Culhane A, Braun D, Choueiri T, Wu C, Wei K, Chan L, Piel B, Ivanova E, Paweletz C, Barbie D, Jenning R, Ficial M, Sticco-Ivins M, Signoretti S, Freeman G, Zhu Q, Marasco W. Achieve clear cell renal cell carcinoma (CCRCC) cures through dual-targeted fine-tuned immune restoring (DFIR) CAR-T cell therapy Cytotherapy 2021, 23: s93. DOI: 10.1016/s1465324921004126.

Braun DA, Street K, Burke KP, Cookmeyer DL, Denize T, Pedersen CB, Gohil SH, Schindler N, Pomerance L, Hirsch L, Bakouny Z, Hou Y, Forman J, Huang T, Li S, Cui A, Keskin DB, Steinharter J, Bouchard G, Sun M, Pimenta EM, Xu W, Mahoney KM, McGregor BA, Hirsch MS, Chang SL, Livak KJ, McDermott DF, Shukla SA, Olsen LR, Signoretti S, Sharpe AH, Irizarry RA, Choueiri TK, Wu CJ. Progressive immune dysfunction with advancing disease stage in renal cell carcinoma Cancer Cell 2021, 39: 632-648.e8. PMID: 33711273, PMCID: PMC8138872, DOI: 10.1016/j.ccell.2021.02.013.

Braun DA, Bakouny Z, Hirsch L, Flippot R, Van Allen EM, Wu CJ, Choueiri TK. Beyond conventional immune-checkpoint inhibition — novel immunotherapies for renal cell carcinoma Nature Reviews Clinical Oncology 2021, 18: 199-214. PMID: 33437048, PMCID: PMC8317018, DOI: 10.1038/s41571-020-00455-z.

Li H, Bullock K, Gurjao C, Braun D, Shukla S, Bosse D, Lalani A, Gopal S, Jin C, Horak C, Wind-Rotolo M, Signoretti S, McDermott D, Freeman G, Van Allen E, Schreiber S, Hodi F, Sellers W, Garraway L, Clish C, Choueiri T, Giannakis M. Abstract NG13: Metabolomic adaptations and correlates of survival to immune checkpoint blockade Cancer Research 2020, 80: ng13-ng13. DOI: 10.1158/1538-7445.am2020-ng13.

Braun DA, Hou Y, Bakouny Z, Ficial M, Sant’ Angelo M, Forman J, Ross-Macdonald P, Berger AC, Jegede OA, Elagina L, Steinharter J, Sun M, Wind-Rotolo M, Pignon JC, Cherniack AD, Lichtenstein L, Neuberg D, Catalano P, Freeman GJ, Sharpe AH, McDermott DF, Van Allen EM, Signoretti S, Wu CJ, Shukla SA, Choueiri TK. Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma Nature Medicine 2020, 26: 909-918. PMID: 32472114, PMCID: PMC7499153, DOI: 10.1038/s41591-020-0839-y.

McKay R, Xie W, McGregor B, Braun D, Wei X, Kyriakopoulos C, Zakharia Y, Maughan B, Rose T, Stadler W, McDermott D, Harshman L, Choueiri T. Optimized management of nivolumab (Nivo) and ipilimumab (Ipi) in advanced renal cell carcinoma (RCC): A response-based phase II study (OMNIVORE). Journal Of Clinical Oncology 2020, 38: 5005-5005. DOI: 10.1200/jco.2020.38.15_suppl.5005.

Braun D, Hou Y, Bakouny Z, Ficial M, Sant'Angelo M, Ross-Macdonald P, Jegede O, Sun M, Wind-Rotolo M, Pignon J, Neuberg D, Catalano P, Freeman G, Sharpe A, McDermott D, Van Allen E, Signoretti S, Wu C, Shukla S, Choueiri T. Immunogenomic characterization of advanced clear cell renal cell carcinoma treated with PD-1 blockade. Journal Of Clinical Oncology 2020, 38: 5010-5010. DOI: 10.1200/jco.2020.38.15_suppl.5010.

Ficial M, Jegede O, Sant'Angelo M, Moreno S, Braun D, Wind-Rotolo M, Pignon J, Catalano P, Sun M, Van Allen E, Freeman G, Sharpe A, Hodi F, Motzer R, Wu C, Atkins M, McDermott D, Shukla S, Choueiri T, Signoretti S. Evaluation of predictive biomarkers for nivolumab in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) from the CheckMate-025 (CM-025) trial. Journal Of Clinical Oncology 2020, 38: 5023-5023. DOI: 10.1200/jco.2020.38.15_suppl.5023.

Ravi P, Bakouny Z, Flippot R, Braun D, Abou Alaiwi S, Wei X, McGregor B, Kilbridge K, Choudhury A, Harshman L, Choueiri T. Safety and efficacy of retreatment with immune checkpoint inhibitors (ICIs) in patients with metastatic RCC (mRCC) who have previously received an ICI. Journal Of Clinical Oncology 2020, 38: 698-698. DOI: 10.1200/jco.2020.38.6_suppl.698.

Bakouny Z, Braun D, Shukla S, Pan W, Gao X, Hou Y, Flaifel A, Nassar A, Abou Alaiwi S, Flippot R, Steinharter J, Nuzzo P, Ishii Y, Ross-Macdonald P, Lee G, McDermott D, Heng D, Signoretti S, Van Allen E, Choueiri T. Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma (S/R RCC) to reveal potential determinants of poor prognosis and response to immune checkpoint inhibitors (ICI). Journal Of Clinical Oncology 2020, 38: 715-715. DOI: 10.1200/jco.2020.38.6_suppl.715.

Mahoney K, Ross-Macdonald P, Shukla S, Braun D, Song L, Veras E, Wind-Rotolo M, Van Allen E, McDermott D, Hodi F, Choueiri T, Freeman G. Soluble PD-L1 as a marker of progressive disease on nivolumab in kidney cancer. Journal Of Clinical Oncology 2020, 38: 746-746. DOI: 10.1200/jco.2020.38.6_suppl.746.

Flippot R, Bakouny Z, Wei X, Braun D, McGregor B, Steinharter J, Harshman L, Vaishampayan U, Severgnini M, McDermott D, Hodi F, Lee G, Van Allen E, Signoretti S, Choueiri T, McKay R. Circulating immune cell populations and cytokines in patients with metastatic variant histology renal cell carcinoma (vRCC) treated with atezolizumab plus bevacizumab (AB): Dynamic changes on therapy and association with outcomes from a phase II trial. Journal Of Clinical Oncology 2020, 38: 740-740. DOI: 10.1200/jco.2020.38.6_suppl.740.

Abou Alaiwi S, Nassar A, El Bakouny Z, Berchuck J, Nuzzo P, Flippot R, Flaifel A, Steinharter J, Baca S, Margolis C, Vokes N, Du H, Shukla S, Braun D, Signoretti S, Sonpavde G, Kwiatkowski D, Van Allen E, Choueiri T. Association of polybromo-associated BAF (PBAF) complex mutations with overall survival (OS) in cancer patients (pts) treated with checkpoint inhibitors (ICIs). Journal Of Clinical Oncology 2019, 37: 103-103. DOI: 10.1200/jco.2019.37.15_suppl.103.

Bakouny Z, Vokes N, Gao X, Nassar A, Abou Alaiwi S, Flippot R, Bouchard G, Steinharter J, Nuzzo P, Pan W, Flaifel A, Lee G, Braun D, Wei X, Signoretti S, McGregor B, Harshman L, Van Allen E, Choueiri T. Efficacy of immune checkpoint inhibitors (ICI) and genomic characterization of sarcomatoid and/or rhabdoid (S/R) metastatic renal cell carcinoma (mRCC). Journal Of Clinical Oncology 2019, 37: 4514-4514. DOI: 10.1200/jco.2019.37.15_suppl.4514.

Pignon J, Jegede O, Shukla S, Braun D, Horak C, Wind-Rotolo M, Ishii Y, Catalano P, Freeman G, Jennings R, De Cubas A, Rathmell K, Choueiri T, Atkins M, McDermott D, Signoretti S. Association of human endogenous retrovirus (hERV) expression with clinical efficacy of PD-1 blockade in metastatic clear cell renal cell carcinoma (mccRCC). Journal Of Clinical Oncology 2019, 37: 4568-4568. DOI: 10.1200/jco.2019.37.15_suppl.4568.

McKay R, McGregor B, Gray K, Steinharter J, Walsh M, Braun D, Flaifel A, VanAllen E, Wei X, Signoretti S, Harshman L, Vaishampayan U, Choueiri T. Results of a phase II study of atezolizumab and bevacizumab in non-clear cell renal cell carcinoma (nccRCC) and clear cell renal cell carcinoma with sarcomatoid differentiation (sccRCC). Journal Of Clinical Oncology 2019, 37: 548-548. DOI: 10.1200/jco.2019.37.7_suppl.548.

Bakouny Z, Flippot R, Braun D, Lalani A, Choueiri T. State of the Future: Translational Approaches in Renal Cell Carcinoma in the Immunotherapy Era European Urology Focus 2019, 6: 37-40. PMID: 30827939, DOI: 10.1016/j.euf.2019.02.014.

Iorgulescu J, Braun D, Oliveira G, Keskin D, Wu C. Acquired mechanisms of immune escape in cancer following immunotherapy Genome Medicine 2018, 10: 87. PMID: 30466478, PMCID: PMC6249768, DOI: 10.1186/s13073-018-0598-2.

Choueiri T, Flaifel A, Xie W, Braun D, Ficial M, Jennings R, Nassar A, Escudier B, George D, Motzer R, Morris M, Powles T, Wang E, Huang Y, Freeman G, Signoretti S. LBA34 PD-L1 status and clinical outcomes to cabozantinib, sunitinib and everolimus in patients with metastatic clear-cell RCC treated on CABOSUN and METEOR clinical trials Annals Of Oncology 2018, 29: viii726. DOI: 10.1093/annonc/mdy424.040.

Wei X, McKay R, Gray K, Stadler W, McDermott D, McGregor B, Agarwal N, Kyriakopoulos C, Carneiro B, Rose T, Zakharia Y, Braun D, Livak K, Wu C, Van Allen E, Signoretti S, Lang J, Hodi F, Choueiri T, Harshman L. Optimized management of nivolumab (NIVO) and ipilimumab (IPI) in advanced renal cell carcinoma (OMNIVORE): A response-based phase II study. Journal Of Clinical Oncology 2018, 36: tps4600-tps4600. DOI: 10.1200/jco.2018.36.15_suppl.tps4600.

Braun D, Wu C. Antigen Discovery and Therapeutic Targeting in Hematologic Malignancies The Cancer Journal 2017, 23: 115-124. PMID: 28410299, PMCID: PMC5856170, DOI: 10.1097/ppo.0000000000000257.

Braun D, Burke K, Van Allen E. Genomic Approaches to Understanding Response and Resistance to Immunotherapy Clinical Cancer Research 2016, 22: 5642-5650. PMID: 27698000, PMCID: PMC5135569, DOI: 10.1158/1078-0432.ccr-16-0066.